- Home
- SPRY vs MLTX Comparison
SPRY vs MLTX Comparison
Compare SPRY & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRY | MLTX |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 979.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SPRY | MLTX |
|---|---|---|
| Price | $9.98 | $15.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $35.00 | $22.22 |
| AVG Volume (30 Days) | 1.8M | ★ 3.6M |
| Earning Date | 03-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $126.72 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5459.66 | N/A |
| 52 Week Low | $6.66 | $5.95 |
| 52 Week High | $18.90 | $62.75 |
Technical Indicators
Market Signals| Indicator | SPRY | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 52.02 |
| Support Level | $10.01 | $15.62 |
| Resistance Level | $10.79 | $16.57 |
| Average True Range (ATR) | 0.68 | 0.98 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 7.25 | 13.59 |
Price Performance
Historical ComparisonAbout SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.